This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph nodes.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00832429.
PRIMARY OBJECTIVES:
I. Identify the rate of SLN (sentinel lymph node) positivity for eyelid sebaceous gland carcinomas.
II. Identify the false negative events associated with SLN biopsy for sebaceous gland carcinomas.
SECONDARY OBJECTIVE:
I. Record any side effects associated with SLN biopsy for sebaceous gland carcinoma of the eyelid.
OUTLINE:
Patients receive technetium Tc 99m sulfur colloid intradermally (ID) and then undergo lymph node mapping and SLN biopsy.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 4 years.
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorBita Esmaeli
